The Evidence-based CKD Clinic: Changing Practice with SGLT2 Inhibition
Published: 20 January 2022
Starting at the waiting room, then through to the consultation, follow-up and patient discharge, explore the role of SGLT2 inhibition in treating CKD, based on efficacy data.
Chair, Prof David Wheeler (University College London, UK) leads the patient-based, data-supported discussion on the renal efficacy and implementation of SGLT2 inhibitors in the treatment of CKD alongside Prof Carol Pollock and Dr Sunita Bavanandan.
After this educational symposium, delegates will:
- Recognise SGLT2 inhibitors as part of the evidence-based CKD treatment landscape
- Understand data supporting the renal efficacy of SGLT2 inhibition in relation to the treatment and clinical outcomes of CKD
- Be able to identify the optimal time to initiate SGLT2 inhibitors in the treatment ofCKD
More from this programme
The Waiting Room
David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.Professor Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, intravenous iron, sodium–glucose co-transporter 2 inhibitors and hypoxia-inducible factor stabilisers in patients with CKD.Professor Wheeler has also been involved in the development of clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-Chair between 2012 and 2019. His ongoing roles include serving as the National Specialty Lead for the National Institute of Health Research…